We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Metastasis Requires Complex Trigger

By Biotechdaily staff writers
Posted on 06 Nov 2003
Researchers using a Drosophila model system have found that a combination of a mutation in the RAS oncogene and the inactivation of any one of a number of genes affecting cell polarity are required to induce tumors to metastasize.

RAS is a family of genes that have many biologic functions but mainly control cell growth and development. More...
Mutations in a RAS gene can lead to uncontrolled cell growth, and more than 30% of lung cancers, 90% of pancreatic cancers, and 50% of colon cancers are associated with mutations at a specific site in the gene K-RAS. Tumors arising from mutations in RAS do not generally metastasize in the fruit fly.

Investigators at Yale University (New Haven, CT, USA) designed a genetic screen to investigate what genes could stimulate RAS-generated tumors to spread. They reported in the October 9, 2003, online edition of Science that the trigger for metastasis required both the presence of a RAS mutation and the inactivation of any one of a number of genes affecting cell polarity. This combination leads to metastatic behavior, including basement membrane degradation, loss of E-cadherin expression, migration, invasion, and secondary tumor formation. Inactivation of these cell polarity genes cannot drive metastatic behavior alone or in combination with other tumor-initiating alterations.

Senior author Dr. Tian Xu, professor and vice chair of the department of genetics at Yale School of Medicine, explained, "By finding common sets of gene mutations that can make a tumor metastasize, this guides us to specific biological processes that can be targeted by drugs to inhibit metastases. It also implies that we may soon have a better ability to detect early on which tumors require the most intensive treatment to stop the progress of cancer.”




Related Links:
Yale University

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.